What is Monopar Therapeutics's net investment in lease?

Monopar Therapeutics (MNPR) reported net investment in lease of $239.88K in Q1 2026.

How has Monopar Therapeutics's net investment in lease changed year-over-year?

Monopar Therapeutics's net investment in lease increased by 2535.5% year-over-year, from $9.1K to $239.88K.

Monopar Therapeutics MNPR Net Investment in Lease

Net Investment in Lease at other companies

Prime MedicinePRME

——

Wave Life SciencesWVE

——

Perspective TherapeuticsCATX

——

Amylyx Pharmaceuticals, Inc.AMLX

——

ArriVent BioPharma, Inc.AVBP

——

PrecigenPGEN

——

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's net investment in lease?: Monopar Therapeutics (MNPR) reported net investment in lease of $239.88K in Q1 2026.
How has Monopar Therapeutics's net investment in lease changed year-over-year?: Monopar Therapeutics's net investment in lease increased by 2535.5% year-over-year, from $9.1K to $239.88K.